Pfizer Inc. $PFE Shares Purchased by Teamwork Financial Advisors LLC

Key Points

• Teamwork Financial Advisors LLC increased its holdings in Pfizer Inc. by 28.8%, owning a total of 64,438 shares valued at approximately $1.56 million as of the end of the second quarter.
• Pacer Advisors Inc. made a significant investment in Pfizer, increasing its stake by 856.8%, now holding over 20 million shares valued at around $508 million.
• Pfizer reported a quarterly EPS of $0.78, exceeding estimates, with revenue reaching $14.65 billion, marking a 10.3% year-over-year increase.

Teamwork Financial Advisors LLC grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 28.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,438 shares of the biopharmaceutical company's stock after buying an additional 14,398 shares during the period. Teamwork Financial Advisors LLC's holdings in Pfizer were worth $1,562,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Wesbanco Bank Inc. boosted its position in shares of Pfizer by 10.6% during the 2nd quarter. Wesbanco Bank Inc. now owns 214,238 shares of the biopharmaceutical company's stock worth $5,193,000 after purchasing an additional 20,474 shares during the period. Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of Pfizer by 12.9% during the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 25,035 shares of the biopharmaceutical company's stock worth $607,000 after purchasing an additional 2,858 shares during the period. Douglas Lane & Associates LLC boosted its position in shares of Pfizer by 2.0% during the 2nd quarter. Douglas Lane & Associates LLC now owns 44,340 shares of the biopharmaceutical company's stock worth $1,075,000 after purchasing an additional 887 shares during the period. Trust Co of the South boosted its position in shares of Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after purchasing an additional 441 shares during the period. Finally, HBW Advisory Services LLC purchased a new position in shares of Pfizer during the 2nd quarter worth approximately $211,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. HSBC lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Bank of America raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Jefferies Financial Group raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Finally, Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Down 3.8%

Shares of PFE traded down $0.95 during midday trading on Friday, reaching $23.91. The stock had a trading volume of 81,158,118 shares, compared to its average volume of 37,472,864. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company's fifty day simple moving average is $24.79 and its two-hundred day simple moving average is $24.27. The company has a market cap of $135.94 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.85 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the business earned $0.60 EPS. The company's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.